Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
1999
Selective Anti-Tumour Agents with Low Toxicity
publication
Evidence: moderate
Author Information
Author(s): Qiu L, Kelso M J, Hansen C, West M L, Fairlie D P, Parsons P G
Primary Institution: Queensland Cancer Fund Laboratories, Queensland Institute of Medical Research
Hypothesis
Hydroxamates can selectively target and kill tumour cells without harming normal cells.
Conclusion
Hydroxamates show potential as selective anti-tumour agents that do not harm normal cells.
Supporting Evidence
- Hydroxamates were selectively toxic to transformed and human tumour cells.
- Normal cells were not harmed at the same concentrations as tumour cells.
- Treatment led to morphological changes in tumour cells towards a more normal appearance.
- Histone H4 acetylation occurred rapidly and was reversible in both tumour and normal cells.
- Two hydroxamates inhibited growth of human melanoma xenografts in mice without developing resistance.
Takeaway
Some special drugs can kill cancer cells without hurting healthy cells, which is really good for treatment.
Methodology
The study involved testing hydroxamates on transformed and human tumour cells and observing their effects in vitro and in vivo.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website